382 related articles for article (PubMed ID: 24441281)
1. Advances in small bowel neuroendocrine neoplasia.
Banck MS; Beutler AS
Curr Opin Gastroenterol; 2014 Mar; 30(2):163-7. PubMed ID: 24441281
[TBL] [Abstract][Full Text] [Related]
2. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
Bousquet C; Lasfargues C; Chalabi M; Billah SM; Susini C; Vezzosi D; Caron P; Pyronnet S
J Clin Endocrinol Metab; 2012 Mar; 97(3):727-37. PubMed ID: 22170729
[TBL] [Abstract][Full Text] [Related]
3. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
Pokuri VK; Fong MK; Iyer R
Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
[TBL] [Abstract][Full Text] [Related]
4. Established clinical use of octreotide and lanreotide in oncology.
Oberg K
Chemotherapy; 2001; 47 Suppl 2():40-53. PubMed ID: 11275701
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Öberg K; Lamberts SW
Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
7. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.
Kidd M; Drozdov I; Joseph R; Pfragner R; Culler M; Modlin I
Cancer; 2008 Aug; 113(4):690-700. PubMed ID: 18618499
[TBL] [Abstract][Full Text] [Related]
8. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
Cives M; Strosberg J
Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials].
Igaz P
Orv Hetil; 2014 Nov; 155(48):1908-12. PubMed ID: 25417137
[TBL] [Abstract][Full Text] [Related]
10. The genomic landscape of small intestine neuroendocrine tumors.
Banck MS; Kanwar R; Kulkarni AA; Boora GK; Metge F; Kipp BR; Zhang L; Thorland EC; Minn KT; Tentu R; Eckloff BW; Wieben ED; Wu Y; Cunningham JM; Nagorney DM; Gilbert JA; Ames MM; Beutler AS
J Clin Invest; 2013 Jun; 123(6):2502-8. PubMed ID: 23676460
[TBL] [Abstract][Full Text] [Related]
11. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
[TBL] [Abstract][Full Text] [Related]
12. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
[TBL] [Abstract][Full Text] [Related]
13. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
14. The management of gastroenteropancreatic neuroendocrine tumors with somatostatin analogues.
Khagi S; Saif MW
JOP; 2014 Jul; 15(4):295-8. PubMed ID: 25076324
[TBL] [Abstract][Full Text] [Related]
15. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.
Ryan P; McBride A; Ray D; Pulgar S; Ramirez RA; Elquza E; Favaro JP; Dranitsaris G
J Oncol Pharm Pract; 2019 Sep; 25(6):1425-1433. PubMed ID: 30924737
[TBL] [Abstract][Full Text] [Related]
16. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.
Aparicio T; Ducreux M; Baudin E; Sabourin JC; De Baere T; Mitry E; Schlumberger M; Rougier P
Eur J Cancer; 2001 May; 37(8):1014-9. PubMed ID: 11334727
[TBL] [Abstract][Full Text] [Related]
17. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.
Capdevila J; Teulé A; Barriuso J; Castellano D; Lopez C; Manzano JL; Alonso V; García-Carbonero R; Dotor E; Matos I; Custodio A; Casanovas O; Salazar R;
Oncologist; 2019 Jan; 24(1):38-46. PubMed ID: 29794066
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours.
Dawod M; Gordoa TA; Cives M; De Mestier L; Crona J; Spada F; Oberg K; Pavel M; Lamarca A
Curr Treat Options Oncol; 2021 Jun; 22(8):73. PubMed ID: 34185197
[TBL] [Abstract][Full Text] [Related]
19. Systemic treatment of neuroendocrine tumors with hepatic metastases.
Demirkan BH; Eriksson B
Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptors: from signaling to clinical practice.
Theodoropoulou M; Stalla GK
Front Neuroendocrinol; 2013 Aug; 34(3):228-52. PubMed ID: 23872332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]